New stock update: Sinocelltech Inc. (688520.SH) has submitted its application to the Hong Kong Stock Exchange.

According to the disclosure of the Hong Kong Stock Exchange on May 22nd, Beijing Sinocelltech Inc. Biotechnology Group Co., Ltd. (688520.SH) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as the exclusive sponsor. According to the prospectus, Sinocelltech Inc. is an innovative biopharmaceutical company focusing on the research, production, and commercialization of therapeutic antibodies, recombinant proteins, and vaccines. Since its establishment in 2002, Sinocelltech Inc. has been committed to independent research and development, establishing an end-to-end development platform to support drug discovery, clinical development, and commercialization. With an integrated technology platform, the company has established a product pipeline covering oncology, autoimmune diseases, ophthalmology, hemophilia, and vaccines.